A Multicenter, Phase 1/2, Open-Label Study Evaluating the Tolerability, Safety, Pharmacokinetics, and Efficacy of AMG 337 in Asian Subjects

Trial Profile

A Multicenter, Phase 1/2, Open-Label Study Evaluating the Tolerability, Safety, Pharmacokinetics, and Efficacy of AMG 337 in Asian Subjects

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs AMG 337 (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 11 Aug 2017 Planned End Date changed from 28 Sep 2017 to 29 Dec 2017.
    • 22 Jun 2017 Planned End Date changed from 1 Jun 2017 to 28 Sep 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top